A novel, pharmacist-led strategy to reduce the prescribing of benzodiazepines in Paisley

By Ian Towle and Joan Adams

Abstract

Aim
To establish and assess a novel strategy to reduce prescribing of benzodiazepines

Design
Prescribing Intervention Study

Subjects and setting
369 patients aged 70 years and under with a repeat benzodiazepine prescription within 1 GP practice with 2 general practitioners.

Outcome measure
Primary outcome measure was number of patients with a benzodiazepine on repeat prescription before and after review. Secondary outcomes were quantities and prescribing rates (items/100patients) of benzodiazepines prescribed measured over a 3 year study period.

Method
After agreement with GPs, a benzodiazepine prescribing policy was developed and implemented. For suitable patients, the pharmacist prepared and calculated a prescription and stepdown regimen and sent a letter to patient inviting them for a GP appointment to discuss their prescription.

Results
96 patients had their prescription inactivated because it had not been requested for 3 months. 206 (56%) patients were invited for review and 151 attended and collected their stepdown regimen. 24 patients receiving a stepdown regimen were restarted on their original (or a lower) dose. Overall 85 (23%) of 369 patients remained on repeat prescription at end of project. Number of benzodiazepine tablets prescribed was reduced by 64% and benzodiazepine prescribing rate decreased by 67%.

Conclusions
The methodology provided a quick and effective method to assist GPs in reducing their benzodiazepine prescribing and was perceived to be a successful and worthwhile investment in time and resources. The pharmacist provided a pivotal role in this project with GP motivation and good communication between members of the team being important contributing factors.

Benzodiazepines, when used short-term, can be rapidly effective and relatively safe in a number of therapeutic areas. However, the long-term prescribing of these drugs is widespread. The British National Formulary recommends that benzodiazepines should not be used for more than a matter of a few weeks. Major clinical problems can occur with long-term use, eg, physical and psychological dependence, and they are recognised as being drugs of potential abuse. In addition, people may develop tolerance to their effects and gain little therapeutic benefit from chronic consumption. Withdrawal of benzodiazepines should always be gradual since abrupt withdrawal may induce a variety of adverse effects. Despite numbers of prescriptions steadily falling, there were still approximately 1.6 million benzodiazepine prescriptions issued in Scotland in 2004 (data on file, ISD).

There is clinical agreement that patients taking benzodiazepines for more than a short period should be regularly reviewed. Several published methodologies aimed at reducing benzodiazepine prescribing with simple interventions such as a letter to patients advising them to cut down or stop benzodiazepines have been shown to be successful.

In the past, pharmacists have provided successful supporting roles in assisting GPs to reduce benzodiazepine prescribing with similar projects, involving sending letters to patients encouraging them to reduce consumption themselves. Another involved the pharmacist inviting patients into a clinic to offer support to those being weaned off benzodiazepines. More recently, the role of the pharmacy technician has been highlighted in assisting with the reduction of benzodiazepine prescribing.

Following discussions with the pharmacist and drug liaison worker, the GPs in a Paisley practice recognised there was a need to address their high benzodiazepine prescribing and a strategy was developed to assist with this. The model drew on knowledge and skills from medical, pharmaceutical and drug misuse services, and enabled practitioners to address different features of the benzodiazepine problem appropriately. The purpose of this project was to assess the impact of a novel, pharmacist-led strategy to reduce benzodiazepine prescribing for patients under 70 years of age. (The review of patients over 70 years old is currently ongoing.) The setting was a two-partner general practice of 3,400 patients in Paisley with a high level of deprivation and high prescribing rate of benzodiazepines. Ethical approval for the project was sought from NHS Argyll and Clyde Local Research Ethics Committee but was deemed not to be required.

Method
A new prescribing policy for benzodiazepines was agreed with the GPs. It involved:

- Initiation of a voluntary ban on the prescribing of benzodiazepines on repeat prescription (unless there were exceptional circumstances)
- A maximum 28-day prescribing interval
- Issuing all new diazepam prescriptions in the 2mg formulation
- Agreeing on a withdrawal (stepdown) protocol

The policy was promoted via posters displayed in the practice, and all practice staff were educated about effective repeat prescribing systems to minimise inappropriate prescribing. The R enfrewshire Drug Service, local prescribing advisers and community pharmacists and Paisley Local Health Care Co-operative were consulted about the new prescribing policy.

The inclusion criteria were patients aged 70 years and under who were on a repeat benzodiazepine prescription. Patients with a specific psychiatric indication for benzodiazepines were excluded and any benzodiazepine not requested in the previous three months was inactivated from repeat prescription, since this was considered a reasonable period for a patient not to require a stepdown regimen. Patient records were reviewed to ascertain the indication for prescribing a ben-
Mr A was prescribed diazepam 5mg three times daily for anxiety and nitrazepam 5mg at night for insomnia in relation to disturbances with neighbours nine months previously. He was now considered appropriate for stepdown.

His repeat prescriptions were inactivated and total daily benzodiazepine dose converted to an equivalent diazepam dose, in this case diazepam 20mg daily (taken as diazepam 2mg tablets) in divided doses.

Two acute prescriptions were generated. The first (given to Mr A at GP consultation) was for diazepam 2mg — nine daily for 14 days reduced by 2mg every 14 days to six daily for 14 days (first stepdown done). The stepdown time period was eight weeks, and was issued for 420 tablets (dispense weekly). The second prescription (retained in the case notes and available to Mr A after eight weeks) was for diazepam 2mg — five daily for 14 days and reduced by 2mg every 14 days to zero. The stepdown time period was 10 weeks, and was issued for 210 tablets (dispense weekly). Total stepdown period was 14 weeks.

An accompanying stepdown chart was given to Mr A, which detailed the administration times for diazepam.

Case study example
late quantities on prescriptions and send letters to patients. This could free pharmacist time to focus on other clinical issues.

Ninety-six patients (26 per cent) had not requested their prescription for three months or more and this number of patients would suggest poor control over the repeat prescribing system with a tendency for GPs to put drugs directly onto repeat prescription instead of issuing an acute prescription. The change to new prescriptions being issued on acute prescription allowed more control over prescribing. There was also a lack of a repeat medication review within this patient group and Zermanski has highlighted this as a major clinical weakness in any repeat prescribing system.10

The secondary outcome data assessed the impact of the project as a whole and not just the patients reviewed. These data included prescribing changes induced by the protocol, prescribing for stepdown regimens in progress, ongoing patients who were excluded or who failed to tolerate the stepdown and patients outside the age criteria. A 64 per cent decrease in the number of benzodiazepine tablets prescribed was mainly caused by a reduction in prescribing of diazepam, nitrazepam and loprazolam and was achieved despite an increase in the number of diazepam tablets (as recommended in protocol). This large change was not only attributable to the stepdown regimens but by a change in the prescribing habits of the GPs.

Patients were followed up to assess compliance with the stepdown regimens and patients who did not attend for benzodiazepine review within two months of their most recent prescription were presumed to have dropped out and the stepdown regimen was withdrawn. Interestingly, 53 patients (26 per cent) who were sent a stepdown letter did not make an appointment to discuss their prescription with the GP and therefore did not receive another prescription. The exact reasons for this are unknown, but it may have been that patients were not taking the drugs in the first place, e.g., they were ordering the prescription and stockpiling the medicine, or passing the prescription to a third party—a well documented source of benzodiazepines diverted to the illicit market.11 It has also been reported that patients may sell part or all of their prescription.12 Subsequently, the policy of not prescribing blue diazepam 10mg was introduced because of its high street value compared with other diazepam strengths. The R enfrewshire Drug Service and Area Drug and Therapeutics Committee both supported this "no 10mg" policy and it subsequently rolled out across N H S Argyll and Clyde.

Limitations There were a number of recognised limitations to this project. Patients were not randomised into the project and compared against a control group, i.e., there was no comparison between those who received a letter only compared with those who saw the GP. In 2004, N I C E concluded that there was no compelling evidence of a clinically useful difference between the "Z" drugs (zopiclone, zolpidem, zolpamid) and shorter-acting benzodiazepine hypnotics from the point of view of their effectiveness, adverse effects or potential for dependence or abuse.12 The extent of "Z" drug prescribing was not investigated in the project, but it is acknowledged that some patients may have been switched from a benzodiazepine to a "Z" drug. On comparison between the study periods, there had only been a 3 per cent increase in "Z" drug prescribing rates, compared with a 17 per cent increase across Scotland but, since the practice rate was still more than double the Scottish average, it is the subject of further work within the practice. Furthermore, the tertiary outcome of GP workload analysis, referrals to counselling or other support network and a patient perspective on the stepdown experience may also have provided useful data on the effectiveness of the project. However, these outcomes did not form part of this project, but could be investigated in a further study.

Conclusions Despite well-documented problems associated with long-term benzodiazepine prescribing, poor control of repeat prescriptions together with multiple other factors can compound the problems of over-prescribing of benzodiazepines. This methodology developed from simple guidance from the B N F, provided a quick and effective method to assist GPs in reducing their benzodiazepine prescribing and was perceived by them to be a successful and worthwhile investment in time and resources.

The pharmacist provided a pivotal role in this project in the development and implementation of a practice policy to promote rational drug therapy. GP motivation and good communication between members of the health care and practice administration team were also important contributing factors. The stepdown programme has subsequently been tried in other localities within N H S Argyll and Clyde and has been met with varying degrees of success, largely dependent on GP motivation.

Pharmacists are suitably skilled to support rational benzodiazepine prescribing, with services ranging from pharmacist-led clinics to offering simple advice and support at the point of dispensing. Within the developing technician’s role, there is an ideal opportunity to facilitate approved stepdown methodologies. In addition, amendments to legislation removing restrictions on benzodiazepine prescribing for supplementary prescribers, further initiatives to reduce over prescribing of benzodiazepines can be achieved in the future.

ACKNOWLEDGEMENTS The authors thank Ian H Amilton, Ian M Ason and the practice staff within St James Medical Centre, Paisley, for all their support and co-operation in this project. The advice of I S D Scotland, A nne C ockroft, mathematics and statistics department, U niversity of Paisley, and Heather A shton, psychopharmacology department, U niversity of N ewcastle, is also gratefully acknowledged.

This paper was accepted for publication on 6 January 2006.

References